• Accepted invitation to appear in a special TV production set for broadcast on Fox Business Network
• Addresses prevention of fraud to improve cash flow
• Opportunity to showcase GRBX, increase value for shareholders and educate viewers in blockchain technology

GreenBox POS, LLC (OTCQB: GRBX), a payment and blockchain solutions entity, recently announced that it has accepted an invitation to appear in a special TV production set for broadcast on Fox Business Network in the September-October timeframe. Top GreenBox executives will be interviewed during this three-part series, and a portion will be filmed at the company’s headquarters in San Diego. Each airing will provide the company with five to six minutes on camera, increasing awareness of the brand, technology and product offerings among an anticipated audience of 95 million households.

“GreenBox technology is superior to all competitors we considered,” Stephen Simon, executive producer for the series, stated in a news release (http://ibn.fm/LdcZ6). “The product line and wealth of knowledge we found at the Company, in addition to the remarkable precise execution, is uniquely positioned for rapid growth. We like this kind of story, and we want to be the first to bring them to mass media.”

GreenBox will address the many concerns that businesses face within the blockchain industry, including prevention of fraud to improve cash flow. The company is a hardware and software technology firm that builds customized payment solutions for different industries, with an emphasis on blockchain-secured ledger technology. Through QuickCard kiosks and e-wallets, point-of-sale solutions, and Loopz, the company is leading the way in a progression toward a cashless society.

Vince Caruso, CEO of FMW Media Works, expressed his excitement at GreenBox’s participating on the program in a recent press release (http://ibn.fm/sBEU5). “I believe their blockchain powered products which include GreenBox POS (point-of-sale), ‘QuickCard,’ ‘LOOPZ,’ and e-wallet, can dominate the payment solutions industry, preventing fraud and improving a business’s efficiency,” he stated. “GreenBox POS’s product offerings make them a great company fit to showcase on both ‘NEW TO THE STREET’ and ‘Exploring the Block’ business TV programs.”

FMW Media Works Corp.’s ‘Exploring the Block’ showcases, questions and explores companies that are changing the way that modern society utilizes blockchain technology in data and security. This is a unique platform for viewers to learn about opportunities and advancements in blockchain invention. GreenBox will be featured in a three-part series providing viewers with the most up-to-date news and insight in this emerging cashless industry. It is an opportunity to showcase all that the company has to offer, increasing value for shareholders and providing education and awareness to viewers.

For more information, visit the company’s website at www.GreenBoxPOS.com

• Wandering is a common behavior among children with autism, affecting approximately 50 percent of families
• GTX Corp’s innovative wearable technology can give children with autism a higher level of independence without exposing them to associated risks
• Recent studies suggest that parents using tracking technology are more comfortable and less concerned about the safety of children with developmental disorders

GTX Corp (OTC: GTXO) recently announced the signing of a collaboration agreement with Autism Society of America. The aim of the partnership is to provide families and individuals aided by the society with a technical solution to enhance their safety and peace of mind, according to a company press release (http://ibn.fm/BDOUe).

Safety concerns are growing among the thousands of families that benefit from the society’s assistance, according to Autism Society of America President Scott Badesch. Wandering is one of the primary concerns, as nearly 50 percent of the children that have been diagnosed with autism will wander. The Centers for Disease Control and Prevention (CDC) reports that one in four children with autism has been missing long enough to cause concern (http://ibn.fm/Zp5dc). Most often, these children and young individuals wander away from their own homes or classrooms. There are several main triggers for such behavior, including enjoyment of exploring, an attempt to get to a place that the child loves, an attempt to leave a stressful situation or the desire to get close to something interesting. This tendency to stray away from safe environments can lead to serious personal safety risks.

A pioneer in the field of wearable GPS technology, GTX Corp will provide children with autism with a much higher level of independence without exposing them to any risk via its dedicated wandering assistive technology.

“Continued technological innovation and partnerships such as the one between Autism Society of America and GTX Corp advance the reality that children with autism can be empowered to have a higher level of independence and quality of life,” GTX Corp CEO Patrick Bertagna stated in a news release. “Healthcare and safety is becoming integrated into our phones, our homes and our clothing with the convergence of digital and medical technologies. Our award-winning GPS SmartSole® and other wander and recovery technologies have been at the forefront of connected health for years, providing new levels of functional oversight, security and peace of mind to a variety of audiences and needs.”

The company has a line of wearable GPS tracking devices, from its GPS SmartSole®, available in three trim-to-fit sizes, to the GPS Invisabelt, offered in two children’s sizes (http://ibn.fm/fDuqv). Under the agreement, every customer referred by the Autism Society will receive a $25 discount on any purchase of a tracking solution, and GTX Corp will make a $25 donation to the Society for every purchase made.

GTX Corp’s flagship product, GPS SmartSole®, is an award-winning GPS solution that integrates innovative safety practices into everyday wearables. SmartSole® will automatically create a location log, tracking a loved one and ensuring both safety and independence. Through the use of SmartSole®, location data is sent to the monitoring system every five minutes. This location is charted on a map, providing a caregiver or a parent with easily identifiable information. Geozone alerts can also be created and sent via email with links to the last known location. Such technology is perceived as one of the most effective options for ensuring the safety of individuals that have an autism spectrum disorder.

A study presented at the 2017 Pediatric Academic Societies meeting suggests that the use of GPS technology reduces the frequency and the risks associated with wandering behaviors among children with autism and various other developmental disorders (http://ibn.fm/0GrtZ). The results were based on a survey carried out among parents. Of those questioned, 23.8 percent reported that they’d used a tracking device at least once. Of those who currently reported using such a tracking device, the vast majority had opted for the technology to ensure peace of mind in terms of safety. Parents using tracking technology also said that they felt more comfortable (81.7 percent) allowing children to spend time with friends when a parent is not available.

The GPS SmartSole® technology may soon become available in the UK as well, through the country’s National Health Service. According to numerous British reports, several organizations that work with people suffering from dementia and Alzheimer’s are pushing for the product’s adoption. The device is currently undergoing tests with dementia patients in Dorset, England (http://ibn.fm/3H4le).

For more information, visit the company’s website at www.GTXCorp.com

• DeepMarkit’s Gamify platform meets key marketing objectives
• Global gamification market projected to see 41.8 percent CAGR
• Gamify offers customizable options that turn players into purchasers

Who knew that mobile phone games could evolve into one of the most powerful and effective ways to attract shoppers to browse, buy and bounce back in an online retail space? That’s exactly the technology that the developers at DeepMarkit Inc. (TSX.V: MKT) (OTCQB: MKTDF) are perfecting.

This intriguing marketing approach, known as gamification, applies the principles, design and engagement of gaming to the purpose of generating leads, promoting products, delivering rewards and building brand awareness and customer loyalty — all key objectives in the world of marketing. Recognizing the powerful potential of this innovative marketing approach, DeepMarkit has created a marketing platform called Gamify that allows businesses to build branded games that attract buyers, drive sales and increase return visits.

Valued at approximately $1.7 million in 2015, the global gamification market is on fire, projected to reach more than $22 billion by 2022 — a CAGR of 41.8 percent (http://ibn.fm/mscHv). This extraordinary growth comes as a result of unprecedented access to the online world (one recent U.N. study reveals that more people in the world have access to mobile phones than toilets), with many of those users flocking to online gaming (http://ibn.fm/ZiC7w).

Gamify offers businesses the chance to reach this phenomenal number of potential customers in a format with which those users are familiar. Gamify provides a selection of easily customizable gaming apps featuring a business’s branded e-store; the platform also allows businesses to create tailored landing pages and collect invaluable data and real-time analytics. In addition, Gamify’s patent-pending app includes unique user incentives such as games and prizes, which turn players into purchasers.

“Businesses need a way to stand out from the crowd,” DeepMarkit president and CEO Darold Parken stated in a news release. “DeepMarkit’s gamification platform gives customers that way to stand out and it’s a way that they can afford. That’s the strength of our platform. For a relatively small amount of money, any business can create a very powerful, high-quality customer engagement using gamification.”

The only publicly traded company focused solely on the emerging monetization tool of gamification, DeepMarkit has clearly established itself as a winner in the field, a position that hasn’t gone unnoticed by others. DeepMarkit recently entered into a joint marketing agreement with ITN International (“ITN”), a global leader in trade show data capture and analytics. Gamify’s platform has also attracted a $1.5 million investment from Allstate International LLC in Hong Kong, a strategic move that gives Allstate a 10 percent stake in DeepMarkit and an enviable opportunity to bring the Gamify platform into the burgeoning Asian gaming market.

For more information, visit the company’s website at www.DeepMarkit.com

• Major features finalized under aggressive deadline, with product launch mere weeks away
• Proprietary technology suite tracks cannabis end-to-end with blockchain-protected solution for growers, breeders
• Current cannabis testing system vulnerable, leaving consumers and producers exposed to risk
• Strategic partnership announced to implement BLOCKStrain platform’s benefits into regulatory framework for medical and adult-use cannabis in Canada

Canada’s inexorable march toward full legalization of cannabis for the adult user in both the medical and recreational markets is much anticipated by the public and Vancouver, Canada-based BLOCKStrain Technology Corp. (TSX.V: DNAX). Major features of BLOCKStrain’s proprietary, end-to-end cannabis tracking platform are rapidly being finalized by the company’s development team, Chief Technology Officer Tommy Stephenson said in a news release (http://ibn.fm/b1Zcv). BLOCKStrain’s product team has also assembled a concise on-boarding package and documentation to help jumpstart Licensed Producers (LPs) and testing partners looking to implement BLOCKStrain’s disruptive seed-to-sale platform.

“Getting the on-boarding process protocols completed was mission critical,” Stephenson said in a news release. “This milestone opens the floodgates for the whole ecosystem we have designed. BLOCKStrain’s partners – LPs, testing facilities, labs – can now quickly and efficiently link into our integrated platform without disturbing their core business processes.”

BLOCKStrain’s proprietary enterprise software platform verifies and tracks cannabis products through an intelligent, blockchain-protected database of strain genetics. By registering the genetic identity of a batch of legal cannabis via a DNA Passport™, BLOCKStrain automates the task of ‘gene-to-sale’ tracking and showcases where each verified product was grown, manufactured, shipped and sold. Consumers, producers and regulators can rest assured that cannabis tracked through BLOCKStrain’s system is verified from genome to sale, which means that black market cannabis is unable to enter the blockchain-protected ecosystem, a recent article states (http://ibn.fm/Qj9Yw).

Major features recently finalized by BLOCKStrain’s development team include the “Network & Collaboration” component, which allows all BLOCKStrain partners throughout the chain of custody to log into one central system. Once logged in, all team members can share and collaborate while securing information with different access rights and permission.

Another technical milestone is the “Strain Verification Booking” feature, which allows cultivators and LPs to use an intuitive process for submitting testing types such as genetic, microbiological and chemistry testing and syncing them with required testing protocols. This feature promises to lift a heavy burden for craft cannabis growers who are tasked with leaping over the same regulatory hurdles as the major players.

BLOCKStrain has also entered into a memorandum of understanding with Spire Secure Logistics Inc. (“Spire”), a wholly-owned subsidiary of Friday Night Inc. (CSE: TGIF), for Spire to introduce and implement BLOCKStrain’s proprietary platform to governments throughout Canada. BLOCKStrain and Spire will collaborate on the design and implementation of security programs and infrastructure for the legal distribution and sale of cannabis, a news release states (http://ibn.fm/Ji41J).

“Spire is amongst the global leaders in providing regulatory and security programming for the cannabis industry, and BLOCKStrain provides an automated, intelligent and secure software solution that verifies and tracks cannabis products through an immutable record of legal genetics,” BLOCKStrain CEO Robert Galarza added in a news release. “Together, we are determined to provide a world-class solution in cannabis logistics security to our customers.”

The global cannabis market is expected to reach $146.4 billion by the end of 2025, according to a new report by Grand View Research (http://ibn.fm/wVh84). This growth potential is tied to a booming market that includes vertical avenues in the medical field amid a growing body of research into new cannabis strains targeting medicinal applications. The Canadian government’s self-imposed October 17, 2018, deadline (http://ibn.fm/orVG6) to allow recreational and medical cannabis for adult users nationwide through retail and online sales has those in the cannabis space moving quickly to secure their places in history.

For more information, visit the company’s website at www.BLOCKStrain.io

• Handheld technology platform in development to deliver high sensitivity, laboratory accuracy testing for cardiac biomarkers at the point of care
• Cardiac biomarker testing market expected to reach $7.2 billion this year
• Major potential for the patented technology to be applied to the detection of numerous other conditions, including cancer, HIV, hepatitis, autoimmune diseases and many others

With cardiovascular disease being the leading cause of death globally for both men and women, and one in four Americans dying of heart disease every year (http://ibn.fm/GD0Ea), the need for more accurate and faster cardiac diagnostic methods is more than evident. Health care technology company Zenosense, Inc. (OTCQB: ZENO) aims to address this issue through the development of transformational medical diagnostic technology that can offer true laboratory-level accuracy of results at the point of care.

The company’s flagship product, being developed through joint venture MIDS Medical Limited (www.MIDSMed.com), is a handheld diagnostic device for cardiac emergency triage called MIDS Cardiac™. The technology is being developed for use at the point of care, with the goal of ensuring rapid and accurate testing of cardiac markers and delivering results that are at least as accurate and sensitive as laboratory tests.

The MIDS Cardiac technology is predicated on nano-magnetic detection of assay beads, a new way of cost-effectively and highly sensitively detecting and measuring diagnostic assays.

Combining patented MIDS nano-magnetic detection technology with the solid technical expertise of its development team, MIDS Cardiac™ aims to revolutionize the diagnosis and management of Acute Myocardial Infarction (AMI). Set to support high sensitivity tests to identify AMI, the technology is being developed for the rapid detection of very low levels of cardiac markers, with a primary focus on troponin I and T, within minutes, including single troponin test results within three minutes and additional biomarkers within eight minutes. This would provide first responders with a new level of analysis at the point of care and would save valuable time during the so-called “golden hour,” when critical treatment is crucial.

MIDS Cardiac is designed to be considerably more cost-effective than laboratory analyzers and to be used by minimally trained personnel. Its largely automated operation will require little manual intervention and expert interpretation of results will not be required. Zenosense believes that this ease of use and affordability, coupled with testing speed and accuracy, could help revolutionize cardiac diagnostics and drive global demand in a multi-billion-dollar market.

The cardiac biomarker testing market is expected to reach $7.2 billion this year, of which $1.16 billion is to be served by point of care devices, according to BCC Research (http://ibn.fm/fCVxS). While China is the fastest growing segment in this market (advancing at a compound annual growth rate of 18.6 percent), the largest regional segment is the United States, which is expected to reach $3.1 billion this year as a result of the growing point of care testing market, the development of new congestive heart failure biomarkers and the approval or new stroke biomarkers.

The MIDS Cardiac device would not only help save countless lives with its fast and accurate diagnostic process to speed intervention, it would also help lower the significant financial burden of monitoring and eliminating suspected AMI cases in the health care system. According to Zenosense, about 85 percent of patients experiencing chest pain do not actually have AMI, so correct and timely diagnosis can eliminate the cost of unnecessary admissions and misdiagnoses, which can amount to billions of dollars per year.

A successful development of MIDS Cardiac is just the first step in the development of a wider technology platform that could be adapted to a wide range of point of care immunoassay tests, based on the same concepts of speed, accuracy, ease of use and cost-effectiveness. Zenosense and MIDS Medical Limited are planning to use the platform to develop a multi-capability, highly sensitive point of care device that could test for numerous conditions, including prostate, colorectal and other cancers, inflammatory and autoimmune disease, osteoporosis, endocrine ailments, blood infections, respiratory viruses, meningitis, rheumatism, hepatitis, HIV, chlamydia and many more.

For more information, visit the company’s website at www.Zenosense.com

• Auscrete owns proprietary technology in hybrid insulated lightweight concrete building products manufacturing
• Company’s focus is on the “Green” movement
• Auscrete is finalizing plans to establish a 75 percent company-owned production plant in Ontario, Canada, with a Canadian Investment Group

A building materials manufacturing company based in Washington, Auscrete Corp. (OTC: ASCK) is at the vanguard of the “Green” movement. The company’s mission is to make affordable, technology-driven and eco-friendly housing available to those who were never before given the opportunity to realize the American Dream.

Auscrete Canada Ltd., as the new company is known, was formed to finance the construction and implementation of a manufacturing facility for its building products. The company will use Auscrete’s proprietary technology in hybrid insulated lightweight concrete building products, and it is leveraging this technology to provide a solution for those who want to buy their own solid, energy efficient, essentially fireproof Auscrete homes.

With its emphasis on the “Green” movement, the company is positioned to capitalize on the ever-growing trend toward environmentally friendly and non-toxic products. ConstructConnect noted that green and sustainable construction has developed from a marginal movement to realize mainstream status (http://ibn.fm/hRcM3). It further said that, “Reducing energy usage and water usage are the top environmental issues driving green construction.”

The technology in Auscrete’s products has been shown to considerably reduce energy usage for heating and cooling while only costing around $100 per square foot to construct. The technology has accomplished this via the use of high level insulation, consequently lessening energy pollution.

Now, Auscrete is in the final stages of plans to set up a 75 percent company-owned production plant with a Canadian investment group. The Canadian group will take a 25 percent interest in the facility, which is to be located near London, Ontario. Spiro Sapounas of London, Ontario, leads the Canadian investment group.

This facility can address the need for affordable housing, both across Canada and in the northeastern United States, where the closest U.S. plant is in the Pacific Northwest. The project also has numerous aspects that may make it suitable for government financial involvement and assistance. Sapounas has met with state and federal governments regarding the facility’s eligibility in this regard.

In a recent news release, Auscrete spokesman Lee Odom said, “Based on the conservative model of projections for this facility with a 12-month production level of 300 homes, Annual Revenue of $45 million is expected. Also, those conservative estimates are based on 1,500 sq. ft. homes whereas most are above that average, so in reality, that number could be higher depending on the demographic region.”

The Ontario facility will be similar to Auscrete’s flagship head office facility in Goldendale, Washington. This plant, with projected manufacturing of building products for 300 houses annually, will employ more than 150 people.

GenieBelt noted that in many countries there exists a dearth of housing while population growth is rising, and poverty is widespread (http://ibn.fm/sqNF5). It stated, “One of the solutions to these problems can be sustainable housing, but whether these homes can be made affordable enough for the average Joe to own or rent is another question.”

As a builder of “Green” energy efficient housing and commercial structures made from its lightweight hybrid concrete/insulation wall and roof panels, Auscrete is now taking its expertise into new areas to fulfill affordable housing needs. The Canadian facility project furthers the company’s vision in this regard.

For more information, visit the company’s website at www.AuscreteHomes.com

• PRO 140 single agent therapy is the first successful single agent therapy in the history of HIV for a sub-population of HIV
• Response rate for the company’s innovative PRO 140 nearly doubled after dosage increase
• About 70 percent of phase 3 trial participants treated with higher doses have achieved viral load suppression
• The monotherapy would allow patients to self-administer one dose per week of PRO 140 at home

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) has announced significant developmental progress for its PRO 140 monotherapy for human immunodeficiency virus (HIV) after noticing improved response rates at higher doses of the treatment during phase 3 trials (http://ibn.fm/yuYub). The company has received clearance from the independent Institutional Review Board (IRB) to increase the weekly dose of PRO 140 from 525 mg to 700 mg, according to a company press release.

The dosage increase will apply to all newly enrolled patients but also to current trial participants who failed to maintain suppressed HIV viral load on a lower dose. Approximately 70 percent of trial participants who started PRO 140 at 525 mg and have been undergoing treatment between one and nine months are achieving HIV viral load suppression, according to CytoDyn President and CEO Nader Pourhassan, Ph.D. Increasing the dosage further, to 700 mg per week, is expected to have even better results. “This IRB decision is exciting for patients, our Company and our shareholders, given the potential for a higher patient response rate with PRO 140 as a single agent at the 700 mg dose level,” Pourhassan explained in a news release.

The CytoDyn CEO added that, as the phase 3 trial progresses, exact response rates for participants taking 525 mg per week could vary. So far, there has been a clear distinction between response rates at 525 mg and the lower 350 mg per week. We believe increasing the dosage to 700 mg has the potential to achieve an even higher response rate.

PRO 140 is one of the company’s leading monoclonal antibodies being developed for HIV infection and certain other immunological disorders, including cancer. PRO 140 works by blocking the HIV co-receptor CCR5 on T-cells that block viral entry. Phase 1 and 2 clinical trial results have indicated that PRO 140 has no negative effect on normal immune functions mediated by CCR5, while being able to significantly reduce viral loads in patients. The phase 3 trial aims to assess the safety, tolerability and efficacy of PRO 140 as a long-acting single-agent maintenance therapy for HIV chronic suppression. If successful, this monotherapy would allow patients to safely self-administer once per week at home, without needing to take daily pills any longer.

Participants in the phase 3 clinical trial were screened for CCR5-tropic HIV infection and had a suppressed viral load under an existing highly active antiretroviral therapy when they started the study. At the beginning, participants were administered weekly PRO 140 doses of 350 mg, with roughly 40 percent being able to maintain suppressed viral load at that dosage. After treating the first 150 patients, CytoDyn increased the weekly dose to 525 mg, and a majority of the patients who did not respond to the lower dose were able to successfully re-suppress their viral loads when switching to the increased dosage.

“Patients who achieve suppressed HIV viral load after 10 weeks tend to maintain suppressed viral load.  Interestingly, some patients in our Phase 2b extension study are now achieving suppressed HIV viral load for nearly four years with PRO 140 as a single agent,” Pourhassan added.

Additionally, all phase 3 trial participants that did not respond to PRO 140 were able to safely achieve suppressed HIV viral load when returning to their previous retroviral therapy. “This is a major achievement as patients continue to have options for maintaining HIV viral load suppression,” said one of the main investigators of the phase 2 monotherapy trial, Jacob Lalezari, M.D., director of Quest Clinical Research and assistant clinical professor of medicine at UCSF/Mount Zion Hospital.

Specializing in humanized monoclonal antibodies and their clinical development, CytoDyn’s groundbreaking advancements in treatments for HIV and other immune deficiency viruses are providing ample opportunities for investors. The company intends to develop PRO 140 both as monotherapy and as part of a combination therapy, but also to pursue non-HIV, inflammatory indications where CCR5 and its ligand CCL5 are involved.

For more information, visit the company’s website at www.Cytodyn.com

• U.S. Securities and Exchange Commission continues to review cryptocurrency ETF applications
• Application by Chicago Board Options Exchange generating buzz among investors
• VRCP’s ATM platform helping to strengthen bitcoin’s legitimacy through “spendability” and technological practicality

As the U.S. Securities and Exchange Commission weighs several applications seeking to establish an exchange-traded investment fund (ETF) for the bitcoin cryptocurrency, Virtual Crypto Technologies Inc. (OTCQB: VRCP) is applauding the signs that regulatory sentiment in the United States appears to be shifting in favor of cryptocurrencies, paving the way for anticipated mass adoption of bitcoin (Crypto: BTC) and other cryptocurrencies.

Virtual Crypto Technologies is a company dedicated to making the financial flexibility of cryptocurrencies more accessible to the public through software- and hardware-based payment solutions that elevate the purchase and sale of cryptocurrencies through ATMs, tablets, PCs and/or mobile devices.

As such, Virtual Crypto considers its experience in enabling the rapid exchange of cryptocurrency and traditional fiat currency to be an advantage in positioning the company to capitalize on the ETF debate as expectations rise that the SEC will approve a bitcoin ETF this year, perhaps as early as August.

“The fact that a regulatory body as important as the SEC is seriously considering a Bitcoin ETF, as well as notable development in the cryptocurrency ecosystem such as MasterCard’s intention to allow blockchain currencies to be transacted on traditional payment channels, validates our vision that cryptocurrencies are here to stay and that an era of virtual coins as a payment method for the masses is just around the corner,” Virtual Crypto CEO Alon Dayan stated in a recent news release (http://ibn.fm/Wi9Rl).

Researchers at Imperial College London reported that digital currencies are overcoming doubts about their trustworthiness and usefulness (http://ibn.fm/lzOai), fueling predictions that bitcoin and other cryptocurrencies will become mainstream forms of payment for goods and services within the next decade.

In late July, the SEC issued its latest denial of a bitcoin ETF, finding that the proposed product wasn’t safe enough for investors (http://ibn.fm/ygruE). However, the agency continues to review numerous other bitcoin ETF proposals, such as a fund advanced by the Chicago Board Options Exchange (CBOE) (http://ibn.fm/dlXmh) that has gained significant interest among investors (http://ibn.fm/wlklS). Industry publication Bitcoinist reported on August 2 that one of the four currently active SEC commissioners is continuing to promote cryptocurrency ETFs as an Exchange Act-consistent device for increasing investor opportunities and sustaining important innovation in the nation’s capital markets (http://ibn.fm/0CcO1).

A recent audio press release highlighting Virtual Crypto Technologies’ position notes that the acid test for determining the legitimacy of blockchain-based currencies such as bitcoin is increasingly being defined by their “spendability” and technological practicality (http://ibn.fm/PNOx9).

Virtual Crypto’s technology has helped establish that legitimacy for bitcoin through its bi-directional NetoBit ATM platform, which enables consumers to withdraw cash from their bitcoin accounts and transfer funds to the accounts without the need for banking institution hurdles and their fees. While a variety of altcoin ATMs are proliferating across North America, with more than 73 percent of them located on the continent (http://ibn.fm/WJNo7), the vast majority of those ATMS only provide “one-way” purchasing of crypto funds.

The uniqueness of the platform is visible in its currency exchange transaction validation (CETV) protocols that speed up the completion of cash or fintech transfers through proprietary transaction confirmation that establishes the probability of a transaction being confirmed, even while the verification by multiple miners is taking place. It is currently accessible to the consumer through Android and iOS mobile apps (http://ibn.fm/wGsGI). The products, working together, allow Virtual Crypto to take economic freedom to the next level.

For more information, visit the company’s website at www.Virtual-Crypto.com

• PHVAF inks agreement with Acosta’s National Specialty Sales division to sell to 2,400 retailers across U.S., will later have access to 25,000 more supermarkets, such as Wal-Mart and Target
• Jim Bailey, PHVAF CEO and president, terms crossover distribution into mainstream national retailers a “significant milestone” for the CBD industry; market channel is valued at $4.1 billion
• OKI line to consist of CBD-infused beverages, such as iced tea and flavored infused waters, plus tinctures and capsules; it will be available to consumers in 3Q2018

Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) will launch its OKI brand of premium CBD products to consumers in 3Q2018 after gaining exposure to some 2,400 mainstream retail outlets across the U.S. when it signed an exclusive national agreement with National Specialty Sales (NSS), an Acosta company. Those stores include Whole Foods Market, Sprouts Farmers Market and National Coop Grocers. The total market channel is valued at greater than $4.1 billion in retail sales, PHVAF announced (http://ibn.fm/Vt0YR).

A video presentation of the announcement is available on the company’s YouTube channel (http://ibn.fm/BrCfg).

The partnership also provides the opportunity to access an additional 25,000 national grocery supermarkets such as Wal-Mart, Target, Kroger and others in Acosta’s national sales network. PHVAF and Acosta are working together to develop in-store merchandising, pricing, sampling and other promotions in order to ensure the success of the OKI line. They are also seeking to maintain direct client relationships and in-store inventory levels.

PHVAF is a Vancouver, Canada, based manufacturer of CBD derived from hemp infused into functional foods, beverages and health products. OKI is the company’s newest line of CBD-infused flavored iced tea, flavor-infused waters and tinctures and capsules. PHVAF also offers the Vida line of premium hemp-infused products, which includes Hemp Oil Extract and Hemp Oil Capsules. The company was recently uplisted to the OTCQX Best Market (http://ibn.fm/dspRQ).

Acosta is a premier food and beverage brokerage agency with more than 100 offices across the U.S. and Canada. Its NSS division has more than 475 sales associates managing the 2,400 retail natural specialty grocery stores.

In a news release, Jim Bailey, CEO and president of PHVAF, said, “This exclusive national agreement with Acosta and NSS is a major growth opportunity for Phivida, and a significant milestone for our industry overall… We are thrilled that Acosta/NSS have selected Phivida as their exclusive CBD beverage company, establishing Phivida’s new OKI label as the first CBD brand to officially cross-over into national mainstream distribution across the USA.”

The launch will begin within the natural/specialty channel, but it is expected that conventional retailers, such as major national grocery stores, will soon follow, according to Doug Campbell, PHVAF’s chief commercial officer.

John Caruso, National SVP-Business Development Strategic Channels at Acosta, added, “CBD-hemp oil infused functional beverages and oil supplements are one of the most exciting new product lines we are bringing to the NSS division… We believe that the team, the OKI brand, and the product quality and marketing strategy make Phivida a cut above the competition and the premier offering within this category. We are excited to bring the OKI products to health and wellness-minded consumers.”

For more information, visit the company’s website at www.Phivida.com

• Earth Science Tech to add three full-spectrum CBD chocolate offerings to product line
• Testing to begin on CBD-based patent products
• Earth Science Tech products will be available to 90,000 retail outlets throughout U.S.

On the heels of a major decision by the U.S. Food and Drug Administration (FDA) to approve Epidiolex, a drug derived from pure cannabidiol (CBD), to treat seizures associated with certain forms of severe epilepsy, Earth Science Tech, Inc. (OTC: ETST) is repositioning its line of full-spectrum CBD offerings.

Included in this move is the announcement that the company, along with joint venture partner Karmavore Superfoods, will be adding three full-spectrum cannabinoid chocolate products to its CBD line. The options — chocolate-covered mangoes, chocolate coconut peppermint cups and chocolate caramelized quinoa crunch — will contain Earth Science Tech’s high-grade cannabinoid oil and raw arriba nacional cacao, as well as other natural organic superfood ingredients. The chocolates are slated to be available during the third quarter of 2018.

In addition, Earth Science is scheduled to start testing on three new CBD-based patent formulas beginning in late 2018 and extending into 2019. In vitro testing on its first batch of formulas will be aimed at demonstrating the superior antioxidant properties and anti-proliferative effects on breast cancer cells. These compelling products are designed to stop inflammation, maintain quality of life and help prevent cancer and other degenerative diseases.

With these highly anticipated new products on the horizon, Earth Science is also focusing on making its products more available to consumers. The company recently signed agreements with AATAC to offer Earth Science’s CBD products to AATAC’s approximately 90,000 retail outlets throughout the United States. Based on growing consumer interest in CBD and positive response to the announcement, AATAC anticipates a high volume of preorders.

“Our association with AATAC, which is an advisory board that focuses on convenience stores, will give us the opportunity to open up and be available to a market that includes every sector of the population,” Jill Buzan, chief sales officer of ETST, stated in the news release. “This could lead to huge exponential growth for ETST’s sales in the next few months.”

This focus on CBD products is designed to solidify Earth Science’s position as a leader in a burgeoning CDB product markets. In the last three years, the hemp-derived CBD market has grown from $90 million to $190 million, and The Hemp Business Journal projects $2.1 billion in total CBD sales by 2020 (http://ibn.fm/ItwyP). This tremendous increase comes as a result of a growing recognition of CBD’s natural health and wellness properties, increased public acceptance and use of the ingredient and the wider accessibility — both online and in brick-and-mortar retail shops — of CBD products.

In addition to manufacturing, marketing and distributing cannabinoid products to the nutraceutical and pharmaceutical markets, Earth Science conducts R&D for low-cost, non-invasive medical devices.

For more information, visit the company’s website at www.EarthScienceTech.com